Global Ischemic Heart Disease (IHD)Drugs Market 2015-2019
IHD is an abnormal condition of the human body marked by narrowing or blocking of the arteries that supply blood to the heart. It results from the buildup of plaque in the arteries. The condition often arises during excitement and exertion when heart requires more blood supply. This leads to recurrent chest pain and discomfort due to lack of sufficient blood supply, a condition known as angina pectoris.
Prolonged blockage of the arteries due to lack of blood supply may result in death of tissues in the heart, leading to myocardial infarction. The symptoms develop slowly, and in most cases the condition is asymptomatic until it reaches the last stages. The common indications include chest pain and shortness of breath. Treatment options are available depending on the condition of the patient. A range of medications of different classes, such as statins, antiplatelet drugs, nitrates, beta-blockers, etc. can be chosen from. Surgical procedures, such as angioplasty and coronary artery bypass graft, are also opted in serious scenarios.
Technavio analysts forecast the global IHD drugs market to grow at a CAGR of 3.61% during 2014-2019.
Covered in this Report
The report covers the present scenario and the growth prospects of the global IHD drugs market for the period 2015-2019. To calculate the market size, we consider the revenue generated from the sales of various branded therapies and generics, along with the drugs used as off-label for the treatment of IHD. IHD includes:
Technavio Announces the Publication of its Research Report – Global Ischemic Heart Disease Drugs Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Ischemic Heart Disease Drugs Market: AstraZeneca plc, Bayer AG, Eli Lilly and Co., Novartis AG, Pfizer Inc. and Sanofi SA
Commenting on the report, an analyst from Technavio’s team said: “The market has huge growth opportunities for vendors because of the growing population of individuals with IHD. To capture maximum market shares and expand the focus area, vendors are investing more on R&D.”
According to the report, the high prevalence of chronic conditions such as hypertension, diabetes, and cholesterol levels are leading to an increase in cardiovascular diseases. The people with diabetes are three to four times more likely to develop CVDs than people without diabetes.
Further, the report states that the availability of effective surgical treatments and the use of catheter based interventions pose a challenge to the growth of market. The need for specific therapeutics at the later stages of the disease leads to the increased reliance on stents and surgeries.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook